{"ticker": {"uuid": "218272cd-de52-44ad-8c23-3cfd49a65802", "symbol": "COGT", "name": "Cogent Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "COGT6232219 Bond Risk Profile", "summary": "This page provides a risk profile for the Cogent Biosciences, Inc. 1.625% 15-NOV-2031 bond, identified by FINRA COGT6232219. It offers an overview of the bond, focusing on credit risk assessment and key metrics for risk analysis. The platform also promises access to exclusive ana", "url": "https://www.tradingview.com/symbols/FINRA-COGT6232219/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-19T12:39:44", "published_display": "19 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT6232219 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a coupon profile for the Cogent Biosciences, Inc. bond COGT6232219, which has a 1.625% interest rate maturing on November 15, 2031. It details the current coupon rate of 1.63% and announces that the next payment is scheduled for November 16, 2026. The page o", "url": "https://www.tradingview.com/symbols/FINRA-COGT6232219/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-18T19:11:47", "published_display": "18 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT6232219 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics and an overview of the COGT6232219 bond issued by Cogent Biosciences, Inc. It details the bond's coupon rate, maturity date, issue date, outstanding amount, and face value. Additionally, it offers a brief description of Cogent Biosciences, Inc. a", "url": "https://www.tradingview.com/symbols/FINRA-COGT6232219/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-18T05:11:47", "published_display": "18 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOUDZsenRVODd6WDltUDdiTS00VC0zbHB2VGNxdVdKeWhBR25YY2tXckI1YnNtS2UxZVQwbmEtWElzczF0Rk5Rd0hPcXViZnV2M0pYeW1QSy1SemFRSWtlOGpWWG0tRHBZVXI5MXZadVVuZzlPb0cza0JKOWl6ZUdNSkg3THhTRDEzTEJTQUNmRUk0S1lRTmNjcjdR?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:56+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its Price to Sales forward metric. The content highlights that market data is provided by ICE Data Services and FactSet, and SEC filings are by Quartr.", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T00:09:19", "published_display": "12 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(COGT) Movement Within Algorithmic Entry Frameworks", "summary": "The article provides an algorithmic analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting strong sentiment across all time horizons and an exceptional risk-reward short setup. It details three trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014wit", "url": "https://news.stocktradersdaily.com/news_release/12/COGT_Movement_Within_Algorithmic_Entry_Frameworks_071126050801_1783804081.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T17:08:00", "published_display": "11 Jul 2026 17:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial data specifically on the enterprise value to EBITDA forward for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a stub or data-focused page from a financial charting and analysis platform, presenting this specific metric for the company. ", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T18:39:20", "published_display": "10 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation", "summary": "Cogent Biosciences has filed a New Drug Application (NDA) with the FDA for bezuclastinib, targeting Advanced Systemic Mastocytosis, following positive trial results. Despite strong recent share price performance, the company's valuation, at a 12.8x Price-to-Book ratio, is conside", "url": "https://www.sahmcapital.com/news/content/cogent-biosciences-cogt-files-fda-application-as-bezuclastinib-hype-meets-a-pricey-valuation-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-10T14:10:22", "published_display": "10 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Bezuclastinib\u2019s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)?", "summary": "Cogent Biosciences has submitted a New Drug Application to the FDA for bezuclastinib, supported by strong data from the APEX trial showing disease modification in advanced systemic mastocytosis. This filing, coupled with ongoing Expanded Access Programs, is a significant catalyst", "url": "https://www.sahmcapital.com/news/content/is-bezuclastinibs-fda-filing-and-disease-modifying-data-altering-the-investment-case-for-cogent-biosciences-cogt-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T03:04:27", "published_display": "10 Jul 2026 03:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial data for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its forward price-to-book ratio. It is a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. The page includes", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T14:45:47", "published_display": "09 Jul 2026 14:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) director takes options in lieu of cash", "summary": "Cogent Biosciences director Karen Jean Ferrante received a grant of 627 stock options on July 1, 2026, as compensation instead of cash fees. These options have an exercise price of $38.48 per share and expire on July 1, 2036. This grant was part of the company's non-employee dire", "url": "https://www.stocktitan.net/sec-filings/COGT/form-4-cogent-biosciences-inc-insider-trading-activity-0673e0937aab.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:52", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides forward-looking enterprise value to revenue data for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a financial data point from TradingView, offering a snapshot of a specific valuation metric. The content is very brief and seems to be a data eleme", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:11:42", "published_display": "05 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT) focusing on its price to earnings forward. It is presented in a data-centric format from TradingView, including market data and reference data from various financial service providers.", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T03:09:17", "published_display": "05 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing", "summary": "Cogent Biosciences (COGT) filed a New Drug Application with the FDA for bezuclastinib, leading to a significant rally in its share price. Despite strong performance and positive trial data, the stock appears pricey with a price-to-book ratio of 12.1x, significantly above the broa", "url": "https://www.sahmcapital.com/news/content/3-reasons-cogent-biosciences-cogt-looks-pricey-after-its-fda-filing-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T12:09:17", "published_display": "03 Jul 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT - Cogent Biosciences Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Cogent Biosciences Inc (COGT). It includes key metrics such as market capitalization, income, sales, P/E ratios, and various performance indicators. The data also presents analyst recommendations and a target pr", "url": "https://finviz.com/stock?t=COGT&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-01T21:40:33", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib", "summary": "Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib, a treatment for Advanced Systemic Mastocytosis, supported by APEX clinical trial findings. Despite this milestone, the company faces challenges indicated by its low GF Score\u2122 of 25/100 and", "url": "https://www.gurufocus.com/news/8938535/cogent-biosciences-cogt-submits-nda-to-fda-for-bezuclastinib", "source_name": "GuruFocus", "published_at": "2026-06-30T22:41:17", "published_display": "30 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (COGT) Movements Inform Risk Allocation Models", "summary": "This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) using AI models, indicating a strong overweight bias across all time horizons. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analy", "url": "https://news.stocktradersdaily.com/news_release/15/How_COGT_Movements_Inform_Risk_Allocation_Models_063026040008_1782849608.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T16:00:00", "published_display": "30 Jun 2026 16:00", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQQnJvTmNLRld2WF9zb1VCTUVCUWhCZW0yRnM4dXhWdFBiOFYzaEdRSHdqdmZMNFlGeW9WSVFzWUQyaUFVRzhsMWtVaEtTblBHN0J2d3N5cDNQZTc0OUxLUFZKdUJMZmh3S0ZJZHo3SkNLSERIaUxhUjZJemFfa2RzVlg5cTBPMjV4SUI1S0VFX2xQemdQbloxOUhtcTFhQktPSUt3QTMtS2tCQlFZY1BpNTJ1dGdpcURvem5VZ3VkNkQwOUk4MXc1RV9ZUzgyLTR5cDlUMkU3WlFWNVYtSDZQMVprcw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-30T13:10:13+00:00", "published_display": "30 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Submission of\u00a0New Drug Application (NDA) for Bezuclastinib\u00a0in Advanced Systemic Mastocytosis (AdvSM)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cogent-biosciences-announces-submission-drug-120000317.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent seeks FDA approval for rare blood disease drug", "summary": "Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for its drug bezuclastinib, targeting advanced systemic mastocytosis (AdvSM). This submission is supported by positive data from the APEX pivotal trial, which showed high objective response rates and a well-", "url": "https://www.stocktitan.net/news/COGT/cogent-biosciences-announces-submission-of-new-drug-application-nda-i86uu9xumyh1.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:49", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Submission of New Drug", "summary": "Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), based on positive data from the APEX pivotal trial. The company expects the drug to receive its first approvals later in 2026, building on s", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319594/0/en/cogent-biosciences-announces-submission-of-new-drug-application-nda-for-bezuclastinib-in-advanced-systemic-mastocytosis-advsm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:09:49", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base", "summary": "Cogent Biosciences (COGT) saw its stock rise 6.7% after its removal from several Russell indices, including the Russell 3000E and Russell 2000 Value. This removal is expected to reshape the company's investor base by shifting out passive institutional money, potentially impacting", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/why-cogent-biosciences-cogt-is-up-67-after-russell-index-rem", "source_name": "Simply Wall Street", "published_at": "2026-06-30T04:09:49", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index", "summary": "Cogent Biosciences, Inc. (NasdaqGS:COGT) has been removed from the Russell Microcap Value Benchmark Index. This news follows several other announcements regarding the company's exclusion from various Russell indices on June 29th and 28th, 2026. Despite these index changes, the co", "url": "https://www.marketscreener.com/news/cogent-biosciences-inc-nasdaqgs-cogt-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfd988f625", "source_name": "marketscreener.com", "published_at": "2026-06-29T22:09:49", "published_display": "29 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew", "summary": "This document from Cogent Biosciences is a Statement of Changes in Beneficial Ownership of Securities, specifically Form 4, related to Director Ros Matthew. It details how the beneficial ownership of Cogent Biosciences securities by Ros Matthew has changed.", "url": "https://www.moomoo.com/news/notice/307512186/cogent-biosciences-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-28T07:10:43", "published_display": "28 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R", "summary": "This document from Cogent Biosciences is a Statement of changes in beneficial ownership of securities (Form 4). It concerns Officer Robbins Andrew R, indicating a change in their security holdings.", "url": "https://www.moomoo.com/news/notice/307363609/cogent-biosciences-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-27T21:10:43", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd", "summary": "This document, titled \"4: Statement of changes in beneficial ownership of securities-Director Shegog Todd,\" indicates a formal filing regarding changes in the beneficial ownership of securities for Todd Shegog, a Director at Cogent Biosciences. Such statements are routinely filed", "url": "https://www.moomoo.com/news/notice/307512190/cogent-biosciences-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-27T10:09:56", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cogent Biosciences, Inc. (COGT) stock, including analyst price targets, historical performance, and financial data. Analysts have a 1-year price forecast, with a max estimate of $72.00 and a min estimate of $35.00. The company's stock has seen", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:41:09", "published_display": "26 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT)", "summary": "This article provides current stock performance data and financial estimates for Cogent Biosciences, Inc. (COGT). It covers recent stock price movements, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnings reports, along with financial metri", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:24:51", "published_display": "26 Jun 2026 19:24", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress", "summary": "Cogent Biosciences Inc. (NASDAQ: COGT) presented promising preclinical data for its novel JAK2 V617F inhibitor, CGT1145, at the 2026 EHA Congress. This candidate, designed to be a best-in-class therapy, shows high selectivity and oral bioavailability, aiming to treat myeloprolife", "url": "https://www.insidermonkey.com/blog/cogent-cogt-presents-preclinical-data-for-novel-jak2-inhibitor-cgt1145-at-2026-eha-congress-1788503/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-24T14:10:41", "published_display": "24 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cogent Biosciences (COGT) \u2019s New Cancer Drug 100 Times More Precise Than What\u2019s Already on the Market?", "summary": "Cogent Biosciences (COGT) has unveiled early-stage preclinical data for its experimental drug CGT1145, presented as a potentially more precise and better-tolerated treatment for certain rare blood cancers. Lab results indicate CGT1145 is over 100-fold selective for a specific gen", "url": "https://uk.finance.yahoo.com/news/cogent-biosciences-cogt-cancer-drug-141434791.html", "source_name": "Market source", "published_at": "2026-06-22T14:11:40", "published_display": "22 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT)", "summary": "Cogent Biosciences presented new data for bezuclastinib in advanced systemic mastocytosis and preclinical results for CGT1145 (a JAK2 V617F inhibitor) at the 2026 European Hematology Association Congress. These findings support bezuclastinib's potential as a multi-indication ther", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/new-bezuclastinib-and-jak2-data-could-be-a-game-changer-for", "source_name": "Simply Wall Street", "published_at": "2026-06-21T06:40:11", "published_display": "21 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxObWdQblY5Wmtmc0pBanUzOVo4bmhEUjNSSFJTc3NRZ0toRXcwaFl1OFQtUDdNYUc2M01aZnpKR2FWR3RxUzhhbWZ3THNiUnpvWGRaYnprZzVkQVhmcmtBd2pjejduVDNpeTNvTnlRV2wzQloxeHl4LV9ST0pQZGNUeXlpNnB5d29LaWV3QmNVLUhEdFdNVHkxa3Z5R1VRdFpHaVF2TjFRWjhyYWxnTXdYZjBhVTJTSmtWN09r?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cogent-biosciences-apos-potential-rare-125831580.html", "source_name": "MT Newswires", "published_at": "2026-06-12T12:58:31+00:00", "published_display": "12 Jun 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cogent-biosciences-announces-preclinical-data-120100395.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T12:01:00+00:00", "published_display": "12 Jun 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cogent-biosciences-announces-detailed-data-120000693.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T12:00:00+00:00", "published_display": "12 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) director linked to option grant for funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPM09mY3c3ZHhiSC1EZEpUWDZfZlFfOW1CWHJ6YnVaZ25YM0FFWEVMWWx2QzBRUURDMTNlbmJXU3lrOVFscWdPOHQ0a1hyam5EWnJJbU56TlJfUmZPb3hPYXZpczFaeFpNVVd5emNLa19VVkZPazIwSTRfczZUZlpSRmVJTEtSSlhaN2xXc0tXS1JSdnVQMXZDS3M5amVZa2dqeGxIek90d0s1ZFBlUE8wTjBIYnppYzA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYXpaVTM5ajlXakViaGxpZlhvc1FxbWpfcnZBSUVWWVJCeWhORlVjSU9BRlh6V3BZY05RLXBXeTQ4NlRWZ1NwdF9HZ0lXVjlPM01TTDZjclJZNVh0Mnh1OVctUUFtYmZlZjVpWm82SDVOV3lOMGV1R0hzX0ZRUl9XdEhhdmZqS3V2MUVSRm9YWlFqOVhpS0J6VGc4blI4VmJiSTZYSm1ub3FhMTdqa2FCclJUT1ZuYUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/investors-may-respond-cogent-biosciences-021301113.html", "source_name": "Simply Wall St.", "published_at": "2026-06-10T02:13:01+00:00", "published_display": "10 Jun 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxONXVOaXYyczhVSVJ5a04xZnFCc0d2SWZCQ1hwZWR4djFwd0F1dFRENGh6dGVFVnM4MTd0WC1SZEhldFFpbzJhenkweGFDUVo1Y2c0UHZ1R3lHcGFSNFRtT3M2R29pcGRnaU43ZGtpVEhqZXBJRmpZRDZlcVVXZlVfbHR3M3IxUE9BMXVQVDNfMWhtc1BXRTRwSHBRTnR6UQ?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Six new Cogent Biosciences hires get stock options and RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcE5hZklQdzNCU3FLbEFKU0xuRmxBY19maEFpVk9xMUpZWElJeEZWZlc5RHpmemxISml4RkszTlZzODlmOWNOeU15TS15ZF9RT2NsN09yQkxaZXF3emlTTnloZlNMVkxLZmEySEpBTHBxYWp0cldpMzRTaXVfMlhSNUR2WU1XdG5FTEpLUDNxalZoTng2TXJaN29HVXBYWEZCR3VUdDNQb0k3bjVMVEwzb20yNlNiT0JqWnpF?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSG4xS2RqSHFsMENDVXFZaXJfZExiTGFqVFEySmZ0RE5GTDQ5dFFGcTZySk1mU0hUV1VFd1pfcm5MOG0zaEs2ek5ScUltaGhLN1dfREpzX0FFYzZObi1Wa29GUEtQQlpXRTV1OUxfaVZWaXIzYXJYNmU4cWRlNVY4OGdXR3NodFNndHlobjRyMTR1MkVrM1BDcjhubTVoR3R1Z3NCT3pmNXV6bm9YQnpkUVJlRnJIMTFzRkVwSA?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOT25fX2hIZEtkWDBiQ3dNWVB5cW5kNGRYUk9LalBlVF9qTWYwVzNMUlo2WjRkRHV5ZUV6YlpVQkNsQWM0WVA4TDhuN0VBY0Q2bUhSVkYzTm1IZnFobUZZN3RYMjMxZ19kQ0NvR3hVMzV2X2h2OVFfLUJLN2NsRzhPcTdGNEV2VnVLU1A0X054QkV0dWNqOVlkZ0RnaHhUMkthSVFvQ2xQdkFBT2N4?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNQThLbTRZYURKT01rOW1HTDZINkRXRVNENkl0TFUxVnNQbjJlR0tVNF9iY2piRldkNVU1cGMzYlhvYmlNak1UTWItYUM5SWEyYW85VjZhWVJLVEE0VERVWUxuWlhjd214YmxYT3FFeld3dHM1VUE2TlAtQ2YyckFkZHB5VUR1RC10UERNcENudE5RTVZOSmo4RGgwUUhFem9KYlNfWnhaREhQODRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPb1lObnowVEdzTk1sTkpvYWxTOXQxck50b2g1T00yTzRJR0ZiZDAzc1BIZVd3SXpTLVBXM0ZERnJwRlhWSlhNZk1QNzk0dmlSX0o4ZFEzbXRGZjd5Tld4Uno3ZF9MV21zalR4WGpmVmpFNjZkTFRJUmQ3NjBmUXhLUm00NDVRQzVJb1FCQWtwbi1fdEVGS2M5MW5oR1BONk1iOF9IeVg0dWY1Yngtb0xiM004d25KbnlSdlFJLWRn?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cogent spotlights a safer KRAS drug and a brain-targeting HER2 therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPcmg1WGtZb01SM3F1UmlzczVsTnM4TXV3QS1MTWhTcFBibExDY3AwcmVqV0hYM2Y5SUR2dXdjWWhMRjh4Rmxkc20yTFZ1RFU1N1ZTTTNLVkJqNDBXV0ZKVXJNanNmRkJCeTFMZkc1WDFjWFdzajAybEFqMTlTTGFWUVBfdGJJNWk5VGhWQmoxOHYxQzFCTzlDd2pEMEc3aGRQN3VFOEhMeXVweGMyZUZpXzZLODNYTDFNOWNlRg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT): Billionaire Stan Druckenmiller Admires Upside Potential of This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOcXY3d2J6b0U5NTlsaUU2c01LUHFiYkxVeGNkeGNwWmxnOEtDeEJMTGNjdVUtZWY3Y0dkMU5RYlVvd2o4bDlDM1JNUHphZzVmNElrX1o5TTFxYlBvMWFrWHRiQlFadmJMUFJPTDFQakdDMFBJT29qcmc3UGt3SHVOUFdtejlUTUVZeVBlcUxhWnlfMllLaXo0UzFHdFB6aTV1ZjF1dkZHTkJRTEd5VWc?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNMXhMTHFLbm5mZ0ZwM2FFY0h4ejl5QVdEZ004ejM2UW1UN0VBODYzMVdKZG1MWU5xanZZT2RiZnZPU1dBakJwd1lkR1UxS0hvY3d5R2M2TnQ3RzFYZ0NiSGYtOWlDMWdObEUyazU2bXNQQU9VLTZKaUlHa0tEMTN2ZHJzN1BpUGt6QlhyckZzb3Z3aFVQZFNpcklCWVV5MmphbldzNi1aQmtvRkVUOG1Weg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPY0M2QVBuT1h3VVFzSFAxdEg2UjNxdm8tMWc0TjZCeTBuRldxUVpnNmRKNF8wOHZUZnpXZ1BpT2FuLVQweDFVUmczRktTaURNd2Y4aEtGZnBHMkpfX2Q0T0UtbkpZVU1iNVptQzZLVk0tb0tncWxzVEwyU2FYZGpHNTd4MjEwSGVaVFJLUDRyMXNPVi14WS1pVVA3TnRqRWctTjVhQmthSGlzM0k?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxONFlNUUNYVnVkZTlQUU8zcDRPajBUbEk0MFZuZDRsRjJ6RENuelRYdUZWVkJ3aVVLQVRTT1dOdE96RElXSFlTblRhdDFfQk4xSmk5c1pUVDFxVXZTRW1nQXJUelF0dHFjTUg0Q3B2emZoSG0wSmplSEhzdHZId3dzSmJOR3A?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPTkY0bk9Nd1JDcmdiWUY0YmZHMzNkTFQ0b245cWVFaXNFdjRqeUt3eU1xZkRCMEE3RDNVdTh1d3QyZkxCRWtqT0wxLVVpZnhJeHNwdVdXellDaVZYX1o5M1ZjTmtzQjdzVERMOFlHZGtrLXJfUzdyaW5mVXpuVHBnVENkR1FCSWZITEM2SQ?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOdm9GOFdmR2FCbWYzTXpod1AyaDF0TlplQWVaaXA0U0xVMVhyNzFsTzhSc2tZYUVUWFhqTFlfaW5fWTRhZk9vUDJUTWxKRHhhT0hReUJNM3NRQ3lQN2ZBM2hKZHdRNUFFUVJYcW9LNlZQR0padFFhTHRXV0txUXViXzlrQk1LaVozWWZ4bWlYelVSTFl6cERUY01FNnVOaEJoelFTT1o1V3NJWlZtejE0SEFzVGlfbDdnRTFob3N3V2xad3QzdHo2djRJZGJ2clY5dEE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "COGT6232219 Bond Risk Profile", "summary": "This page provides a risk profile for the Cogent Biosciences, Inc. 1.625% 15-NOV-2031 bond, identified by FINRA COGT6232219. It offers an overview of the bond, focusing on credit risk assessment and key metrics for risk analysis. The platform also promises access to exclusive ana", "url": "https://www.tradingview.com/symbols/FINRA-COGT6232219/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-19T12:39:44", "published_display": "19 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT6232219 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a coupon profile for the Cogent Biosciences, Inc. bond COGT6232219, which has a 1.625% interest rate maturing on November 15, 2031. It details the current coupon rate of 1.63% and announces that the next payment is scheduled for November 16, 2026. The page o", "url": "https://www.tradingview.com/symbols/FINRA-COGT6232219/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-18T19:11:47", "published_display": "18 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT6232219 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics and an overview of the COGT6232219 bond issued by Cogent Biosciences, Inc. It details the bond's coupon rate, maturity date, issue date, outstanding amount, and face value. Additionally, it offers a brief description of Cogent Biosciences, Inc. a", "url": "https://www.tradingview.com/symbols/FINRA-COGT6232219/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-18T05:11:47", "published_display": "18 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOUDZsenRVODd6WDltUDdiTS00VC0zbHB2VGNxdVdKeWhBR25YY2tXckI1YnNtS2UxZVQwbmEtWElzczF0Rk5Rd0hPcXViZnV2M0pYeW1QSy1SemFRSWtlOGpWWG0tRHBZVXI5MXZadVVuZzlPb0cza0JKOWl6ZUdNSkg3THhTRDEzTEJTQUNmRUk0S1lRTmNjcjdR?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:56+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its Price to Sales forward metric. The content highlights that market data is provided by ICE Data Services and FactSet, and SEC filings are by Quartr.", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T00:09:19", "published_display": "12 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(COGT) Movement Within Algorithmic Entry Frameworks", "summary": "The article provides an algorithmic analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting strong sentiment across all time horizons and an exceptional risk-reward short setup. It details three trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014wit", "url": "https://news.stocktradersdaily.com/news_release/12/COGT_Movement_Within_Algorithmic_Entry_Frameworks_071126050801_1783804081.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T17:08:00", "published_display": "11 Jul 2026 17:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial data specifically on the enterprise value to EBITDA forward for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a stub or data-focused page from a financial charting and analysis platform, presenting this specific metric for the company. ", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T18:39:20", "published_display": "10 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation", "summary": "Cogent Biosciences has filed a New Drug Application (NDA) with the FDA for bezuclastinib, targeting Advanced Systemic Mastocytosis, following positive trial results. Despite strong recent share price performance, the company's valuation, at a 12.8x Price-to-Book ratio, is conside", "url": "https://www.sahmcapital.com/news/content/cogent-biosciences-cogt-files-fda-application-as-bezuclastinib-hype-meets-a-pricey-valuation-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-10T14:10:22", "published_display": "10 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Bezuclastinib\u2019s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)?", "summary": "Cogent Biosciences has submitted a New Drug Application to the FDA for bezuclastinib, supported by strong data from the APEX trial showing disease modification in advanced systemic mastocytosis. This filing, coupled with ongoing Expanded Access Programs, is a significant catalyst", "url": "https://www.sahmcapital.com/news/content/is-bezuclastinibs-fda-filing-and-disease-modifying-data-altering-the-investment-case-for-cogent-biosciences-cogt-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T03:04:27", "published_display": "10 Jul 2026 03:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial data for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its forward price-to-book ratio. It is a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. The page includes", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T14:45:47", "published_display": "09 Jul 2026 14:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) director takes options in lieu of cash", "summary": "Cogent Biosciences director Karen Jean Ferrante received a grant of 627 stock options on July 1, 2026, as compensation instead of cash fees. These options have an exercise price of $38.48 per share and expire on July 1, 2036. This grant was part of the company's non-employee dire", "url": "https://www.stocktitan.net/sec-filings/COGT/form-4-cogent-biosciences-inc-insider-trading-activity-0673e0937aab.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:52", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides forward-looking enterprise value to revenue data for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a financial data point from TradingView, offering a snapshot of a specific valuation metric. The content is very brief and seems to be a data eleme", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:11:42", "published_display": "05 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cogent Biosciences, Inc. \u2013 NASDAQ:COGT", "summary": "This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT) focusing on its price to earnings forward. It is presented in a data-centric format from TradingView, including market data and reference data from various financial service providers.", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T03:09:17", "published_display": "05 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing", "summary": "Cogent Biosciences (COGT) filed a New Drug Application with the FDA for bezuclastinib, leading to a significant rally in its share price. Despite strong performance and positive trial data, the stock appears pricey with a price-to-book ratio of 12.1x, significantly above the broa", "url": "https://www.sahmcapital.com/news/content/3-reasons-cogent-biosciences-cogt-looks-pricey-after-its-fda-filing-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T12:09:17", "published_display": "03 Jul 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT - Cogent Biosciences Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Cogent Biosciences Inc (COGT). It includes key metrics such as market capitalization, income, sales, P/E ratios, and various performance indicators. The data also presents analyst recommendations and a target pr", "url": "https://finviz.com/stock?t=COGT&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-01T21:40:33", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib", "summary": "Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib, a treatment for Advanced Systemic Mastocytosis, supported by APEX clinical trial findings. Despite this milestone, the company faces challenges indicated by its low GF Score\u2122 of 25/100 and", "url": "https://www.gurufocus.com/news/8938535/cogent-biosciences-cogt-submits-nda-to-fda-for-bezuclastinib", "source_name": "GuruFocus", "published_at": "2026-06-30T22:41:17", "published_display": "30 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (COGT) Movements Inform Risk Allocation Models", "summary": "This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) using AI models, indicating a strong overweight bias across all time horizons. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analy", "url": "https://news.stocktradersdaily.com/news_release/15/How_COGT_Movements_Inform_Risk_Allocation_Models_063026040008_1782849608.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T16:00:00", "published_display": "30 Jun 2026 16:00", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQQnJvTmNLRld2WF9zb1VCTUVCUWhCZW0yRnM4dXhWdFBiOFYzaEdRSHdqdmZMNFlGeW9WSVFzWUQyaUFVRzhsMWtVaEtTblBHN0J2d3N5cDNQZTc0OUxLUFZKdUJMZmh3S0ZJZHo3SkNLSERIaUxhUjZJemFfa2RzVlg5cTBPMjV4SUI1S0VFX2xQemdQbloxOUhtcTFhQktPSUt3QTMtS2tCQlFZY1BpNTJ1dGdpcURvem5VZ3VkNkQwOUk4MXc1RV9ZUzgyLTR5cDlUMkU3WlFWNVYtSDZQMVprcw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-30T13:10:13+00:00", "published_display": "30 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Submission of\u00a0New Drug Application (NDA) for Bezuclastinib\u00a0in Advanced Systemic Mastocytosis (AdvSM)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cogent-biosciences-announces-submission-drug-120000317.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent seeks FDA approval for rare blood disease drug", "summary": "Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for its drug bezuclastinib, targeting advanced systemic mastocytosis (AdvSM). This submission is supported by positive data from the APEX pivotal trial, which showed high objective response rates and a well-", "url": "https://www.stocktitan.net/news/COGT/cogent-biosciences-announces-submission-of-new-drug-application-nda-i86uu9xumyh1.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:49", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Submission of New Drug", "summary": "Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), based on positive data from the APEX pivotal trial. The company expects the drug to receive its first approvals later in 2026, building on s", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319594/0/en/cogent-biosciences-announces-submission-of-new-drug-application-nda-for-bezuclastinib-in-advanced-systemic-mastocytosis-advsm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:09:49", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base", "summary": "Cogent Biosciences (COGT) saw its stock rise 6.7% after its removal from several Russell indices, including the Russell 3000E and Russell 2000 Value. This removal is expected to reshape the company's investor base by shifting out passive institutional money, potentially impacting", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/why-cogent-biosciences-cogt-is-up-67-after-russell-index-rem", "source_name": "Simply Wall Street", "published_at": "2026-06-30T04:09:49", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index", "summary": "Cogent Biosciences, Inc. (NasdaqGS:COGT) has been removed from the Russell Microcap Value Benchmark Index. This news follows several other announcements regarding the company's exclusion from various Russell indices on June 29th and 28th, 2026. Despite these index changes, the co", "url": "https://www.marketscreener.com/news/cogent-biosciences-inc-nasdaqgs-cogt-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfd988f625", "source_name": "marketscreener.com", "published_at": "2026-06-29T22:09:49", "published_display": "29 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew", "summary": "This document from Cogent Biosciences is a Statement of Changes in Beneficial Ownership of Securities, specifically Form 4, related to Director Ros Matthew. It details how the beneficial ownership of Cogent Biosciences securities by Ros Matthew has changed.", "url": "https://www.moomoo.com/news/notice/307512186/cogent-biosciences-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-28T07:10:43", "published_display": "28 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R", "summary": "This document from Cogent Biosciences is a Statement of changes in beneficial ownership of securities (Form 4). It concerns Officer Robbins Andrew R, indicating a change in their security holdings.", "url": "https://www.moomoo.com/news/notice/307363609/cogent-biosciences-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-27T21:10:43", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd", "summary": "This document, titled \"4: Statement of changes in beneficial ownership of securities-Director Shegog Todd,\" indicates a formal filing regarding changes in the beneficial ownership of securities for Todd Shegog, a Director at Cogent Biosciences. Such statements are routinely filed", "url": "https://www.moomoo.com/news/notice/307512190/cogent-biosciences-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-27T10:09:56", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COGT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cogent Biosciences, Inc. (COGT) stock, including analyst price targets, historical performance, and financial data. Analysts have a 1-year price forecast, with a max estimate of $72.00 and a min estimate of $35.00. The company's stock has seen", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:41:09", "published_display": "26 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT)", "summary": "This article provides current stock performance data and financial estimates for Cogent Biosciences, Inc. (COGT). It covers recent stock price movements, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnings reports, along with financial metri", "url": "https://www.tradingview.com/symbols/NASDAQ-COGT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:24:51", "published_display": "26 Jun 2026 19:24", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress", "summary": "Cogent Biosciences Inc. (NASDAQ: COGT) presented promising preclinical data for its novel JAK2 V617F inhibitor, CGT1145, at the 2026 EHA Congress. This candidate, designed to be a best-in-class therapy, shows high selectivity and oral bioavailability, aiming to treat myeloprolife", "url": "https://www.insidermonkey.com/blog/cogent-cogt-presents-preclinical-data-for-novel-jak2-inhibitor-cgt1145-at-2026-eha-congress-1788503/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-24T14:10:41", "published_display": "24 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cogent Biosciences (COGT) \u2019s New Cancer Drug 100 Times More Precise Than What\u2019s Already on the Market?", "summary": "Cogent Biosciences (COGT) has unveiled early-stage preclinical data for its experimental drug CGT1145, presented as a potentially more precise and better-tolerated treatment for certain rare blood cancers. Lab results indicate CGT1145 is over 100-fold selective for a specific gen", "url": "https://uk.finance.yahoo.com/news/cogent-biosciences-cogt-cancer-drug-141434791.html", "source_name": "Market source", "published_at": "2026-06-22T14:11:40", "published_display": "22 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT)", "summary": "Cogent Biosciences presented new data for bezuclastinib in advanced systemic mastocytosis and preclinical results for CGT1145 (a JAK2 V617F inhibitor) at the 2026 European Hematology Association Congress. These findings support bezuclastinib's potential as a multi-indication ther", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/new-bezuclastinib-and-jak2-data-could-be-a-game-changer-for", "source_name": "Simply Wall Street", "published_at": "2026-06-21T06:40:11", "published_display": "21 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxObWdQblY5Wmtmc0pBanUzOVo4bmhEUjNSSFJTc3NRZ0toRXcwaFl1OFQtUDdNYUc2M01aZnpKR2FWR3RxUzhhbWZ3THNiUnpvWGRaYnprZzVkQVhmcmtBd2pjejduVDNpeTNvTnlRV2wzQloxeHl4LV9ST0pQZGNUeXlpNnB5d29LaWV3QmNVLUhEdFdNVHkxa3Z5R1VRdFpHaVF2TjFRWjhyYWxnTXdYZjBhVTJTSmtWN09r?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cogent-biosciences-apos-potential-rare-125831580.html", "source_name": "MT Newswires", "published_at": "2026-06-12T12:58:31+00:00", "published_display": "12 Jun 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cogent-biosciences-announces-preclinical-data-120100395.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T12:01:00+00:00", "published_display": "12 Jun 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cogent-biosciences-announces-detailed-data-120000693.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T12:00:00+00:00", "published_display": "12 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) director linked to option grant for funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPM09mY3c3ZHhiSC1EZEpUWDZfZlFfOW1CWHJ6YnVaZ25YM0FFWEVMWWx2QzBRUURDMTNlbmJXU3lrOVFscWdPOHQ0a1hyam5EWnJJbU56TlJfUmZPb3hPYXZpczFaeFpNVVd5emNLa19VVkZPazIwSTRfczZUZlpSRmVJTEtSSlhaN2xXc0tXS1JSdnVQMXZDS3M5amVZa2dqeGxIek90d0s1ZFBlUE8wTjBIYnppYzA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOYXpaVTM5ajlXakViaGxpZlhvc1FxbWpfcnZBSUVWWVJCeWhORlVjSU9BRlh6V3BZY05RLXBXeTQ4NlRWZ1NwdF9HZ0lXVjlPM01TTDZjclJZNVh0Mnh1OVctUUFtYmZlZjVpWm82SDVOV3lOMGV1R0hzX0ZRUl9XdEhhdmZqS3V2MUVSRm9YWlFqOVhpS0J6VGc4blI4VmJiSTZYSm1ub3FhMTdqa2FCclJUT1ZuYUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/investors-may-respond-cogent-biosciences-021301113.html", "source_name": "Simply Wall St.", "published_at": "2026-06-10T02:13:01+00:00", "published_display": "10 Jun 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxONXVOaXYyczhVSVJ5a04xZnFCc0d2SWZCQ1hwZWR4djFwd0F1dFRENGh6dGVFVnM4MTd0WC1SZEhldFFpbzJhenkweGFDUVo1Y2c0UHZ1R3lHcGFSNFRtT3M2R29pcGRnaU43ZGtpVEhqZXBJRmpZRDZlcVVXZlVfbHR3M3IxUE9BMXVQVDNfMWhtc1BXRTRwSHBRTnR6UQ?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Six new Cogent Biosciences hires get stock options and RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcE5hZklQdzNCU3FLbEFKU0xuRmxBY19maEFpVk9xMUpZWElJeEZWZlc5RHpmemxISml4RkszTlZzODlmOWNOeU15TS15ZF9RT2NsN09yQkxaZXF3emlTTnloZlNMVkxLZmEySEpBTHBxYWp0cldpMzRTaXVfMlhSNUR2WU1XdG5FTEpLUDNxalZoTng2TXJaN29HVXBYWEZCR3VUdDNQb0k3bjVMVEwzb20yNlNiT0JqWnpF?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSG4xS2RqSHFsMENDVXFZaXJfZExiTGFqVFEySmZ0RE5GTDQ5dFFGcTZySk1mU0hUV1VFd1pfcm5MOG0zaEs2ek5ScUltaGhLN1dfREpzX0FFYzZObi1Wa29GUEtQQlpXRTV1OUxfaVZWaXIzYXJYNmU4cWRlNVY4OGdXR3NodFNndHlobjRyMTR1MkVrM1BDcjhubTVoR3R1Z3NCT3pmNXV6bm9YQnpkUVJlRnJIMTFzRkVwSA?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOT25fX2hIZEtkWDBiQ3dNWVB5cW5kNGRYUk9LalBlVF9qTWYwVzNMUlo2WjRkRHV5ZUV6YlpVQkNsQWM0WVA4TDhuN0VBY0Q2bUhSVkYzTm1IZnFobUZZN3RYMjMxZ19kQ0NvR3hVMzV2X2h2OVFfLUJLN2NsRzhPcTdGNEV2VnVLU1A0X054QkV0dWNqOVlkZ0RnaHhUMkthSVFvQ2xQdkFBT2N4?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNQThLbTRZYURKT01rOW1HTDZINkRXRVNENkl0TFUxVnNQbjJlR0tVNF9iY2piRldkNVU1cGMzYlhvYmlNak1UTWItYUM5SWEyYW85VjZhWVJLVEE0VERVWUxuWlhjd214YmxYT3FFeld3dHM1VUE2TlAtQ2YyckFkZHB5VUR1RC10UERNcENudE5RTVZOSmo4RGgwUUhFem9KYlNfWnhaREhQODRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPb1lObnowVEdzTk1sTkpvYWxTOXQxck50b2g1T00yTzRJR0ZiZDAzc1BIZVd3SXpTLVBXM0ZERnJwRlhWSlhNZk1QNzk0dmlSX0o4ZFEzbXRGZjd5Tld4Uno3ZF9MV21zalR4WGpmVmpFNjZkTFRJUmQ3NjBmUXhLUm00NDVRQzVJb1FCQWtwbi1fdEVGS2M5MW5oR1BONk1iOF9IeVg0dWY1Yngtb0xiM004d25KbnlSdlFJLWRn?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent spotlights a safer KRAS drug and a brain-targeting HER2 therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPcmg1WGtZb01SM3F1UmlzczVsTnM4TXV3QS1MTWhTcFBibExDY3AwcmVqV0hYM2Y5SUR2dXdjWWhMRjh4Rmxkc20yTFZ1RFU1N1ZTTTNLVkJqNDBXV0ZKVXJNanNmRkJCeTFMZkc1WDFjWFdzajAybEFqMTlTTGFWUVBfdGJJNWk5VGhWQmoxOHYxQzFCTzlDd2pEMEc3aGRQN3VFOEhMeXVweGMyZUZpXzZLODNYTDFNOWNlRg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences (COGT): Billionaire Stan Druckenmiller Admires Upside Potential of This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOcXY3d2J6b0U5NTlsaUU2c01LUHFiYkxVeGNkeGNwWmxnOEtDeEJMTGNjdVUtZWY3Y0dkMU5RYlVvd2o4bDlDM1JNUHphZzVmNElrX1o5TTFxYlBvMWFrWHRiQlFadmJMUFJPTDFQakdDMFBJT29qcmc3UGt3SHVOUFdtejlUTUVZeVBlcUxhWnlfMllLaXo0UzFHdFB6aTV1ZjF1dkZHTkJRTEd5VWc?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNMXhMTHFLbm5mZ0ZwM2FFY0h4ejl5QVdEZ004ejM2UW1UN0VBODYzMVdKZG1MWU5xanZZT2RiZnZPU1dBakJwd1lkR1UxS0hvY3d5R2M2TnQ3RzFYZ0NiSGYtOWlDMWdObEUyazU2bXNQQU9VLTZKaUlHa0tEMTN2ZHJzN1BpUGt6QlhyckZzb3Z3aFVQZFNpcklCWVV5MmphbldzNi1aQmtvRkVUOG1Weg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPY0M2QVBuT1h3VVFzSFAxdEg2UjNxdm8tMWc0TjZCeTBuRldxUVpnNmRKNF8wOHZUZnpXZ1BpT2FuLVQweDFVUmczRktTaURNd2Y4aEtGZnBHMkpfX2Q0T0UtbkpZVU1iNVptQzZLVk0tb0tncWxzVEwyU2FYZGpHNTd4MjEwSGVaVFJLUDRyMXNPVi14WS1pVVA3TnRqRWctTjVhQmthSGlzM0k?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxONFlNUUNYVnVkZTlQUU8zcDRPajBUbEk0MFZuZDRsRjJ6RENuelRYdUZWVkJ3aVVLQVRTT1dOdE96RElXSFlTblRhdDFfQk4xSmk5c1pUVDFxVXZTRW1nQXJUelF0dHFjTUg0Q3B2emZoSG0wSmplSEhzdHZId3dzSmJOR3A?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPTkY0bk9Nd1JDcmdiWUY0YmZHMzNkTFQ0b245cWVFaXNFdjRqeUt3eU1xZkRCMEE3RDNVdTh1d3QyZkxCRWtqT0wxLVVpZnhJeHNwdVdXellDaVZYX1o5M1ZjTmtzQjdzVERMOFlHZGtrLXJfUzdyaW5mVXpuVHBnVENkR1FCSWZITEM2SQ?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOdm9GOFdmR2FCbWYzTXpod1AyaDF0TlplQWVaaXA0U0xVMVhyNzFsTzhSc2tZYUVUWFhqTFlfaW5fWTRhZk9vUDJUTWxKRHhhT0hReUJNM3NRQ3lQN2ZBM2hKZHdRNUFFUVJYcW9LNlZQR0padFFhTHRXV0txUXViXzlrQk1LaVozWWZ4bWlYelVSTFl6cERUY01FNnVOaEJoelFTT1o1V3NJWlZtejE0SEFzVGlfbDdnRTFob3N3V2xad3QzdHo2djRJZGJ2clY5dEE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 65, "sentiment_summary": {"positive": 16, "negative": 6, "neutral": 43, "score": 54, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 23.8, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.0, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 39.08, "latest_week": "2026-07-17", "one_week_move": 0.5, "four_week_move": 13.1, "twelve_week_move": 6.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.475589, "market_dynamics_buy_signal": false, "relative_strength": 20.794217, "fair_value_gap": 155.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.8987, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.5% over one week, +13.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "Sahm", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 15}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.5% over one week, +13.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "COGT6232219 Bond Risk Profile"}], "updated_at": "2026-07-19T17:47:27.809424+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}